DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Smartphone Technology to Alleviate Malignant Pain (STAMP)

Not Applicable

Completed

Conditions: Pain Management
Cancer
Opioid Use

Interventions: Behavioral: Intervention Participants

First Posted Date: 2018-10-24

Last Posted Date: 2023-06-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT03717402

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Testosterone Cypionate 100 MG/ML
Drug: Placebo

First Posted Date: 2018-10-23

Last Posted Date: 2024-12-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 134

Registration Number: NCT03716739

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2018-10-23

Last Posted Date: 2023-09-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT03716180

Locations: 🇺🇸
DF/BWCC in clinical affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 2 locations

Mindfulness-Music Intervention for Adolescents and Young Adults With Cancer

Not Applicable

Completed

Conditions: Anxiety
Stress
Oncology

Interventions: Behavioral: Music-based meditation

First Posted Date: 2018-10-17

Last Posted Date: 2022-11-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 38

Registration Number: NCT03709225

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: Daunorubicin
Drug: Cytarabine

First Posted Date: 2018-10-17

Last Posted Date: 2024-08-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 64

Registration Number: NCT03709758

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia

Phase 2

Completed

Conditions: Leukoplakia, Oral

Interventions: Drug: Nivolumab

First Posted Date: 2018-10-02

Last Posted Date: 2024-09-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 33

Registration Number: NCT03692325

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

Recruiting

Conditions: Multiple Myeloma

Interventions: Other: Sample of Blood

First Posted Date: 2018-09-28

Last Posted Date: 2024-08-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30000

Registration Number: NCT03689595

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

Not Applicable

Recruiting

Conditions: Mesothelioma

Interventions: Other: MPT Test
Other: CLDN15/VIM Test

First Posted Date: 2018-09-25

Last Posted Date: 2023-01-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 240

Registration Number: NCT03683680

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Endometrial Cancer
Ovarian Cancer

Interventions: Drug: Letrozole
Drug: Abemaciclib
Drug: LY3023414
Drug: Zotatifin
Drug: Metformin

First Posted Date: 2018-09-18

Last Posted Date: 2024-11-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 130

Registration Number: NCT03675893

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Phase 2

Active, not recruiting

Conditions: Uterine Cancer

Interventions: Drug: AZD1775

First Posted Date: 2018-09-12

Last Posted Date: 2024-01-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 49

Registration Number: NCT03668340

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy